Summary The anti-emetic efficacy and safety of granisetron, a highly selective and potent 5-HT3 receptor antagonist, was compared with that of high-dose metoclopramide plus dexamethasone in 281 patients due to receive single-day cisplatin chemotherapy (,>49 mg m-). In this single-blind, multicentre study, granisetron (40 1tg kg-') was administered as a single prophylactic 5-min infusion. Dexamethasone (12 mg) was administered as a 30-min infusion followed by a loading dose of 3 mg kg-' metoclopramide. A maintenance dose of metoclopramide 4 mg kg-' was then infused over 8 h. A single prophylactic dose of granisetron was as effective as the combination regimen in the prevention of cisplatin-induced emesis. Of 143 granisetron-treated patients, 100 (70%) were complete responders (no vomiting and no or only mild nausea) compared with 93/138 (67%) patients who received the comparator regimen. Twenty-three percent of granisetron-treated patients experienced one of more adverse events compared with 33% of patients in the comparator group. No extrapyramidal reactions were reported in the granisetron group compared with 13 in comparator-treated patients (8%). This difference was significant (P<0.05). The commonest adverse event in the granisetron group, headache (9.8%) described by the majority of patients as mild, was significantly higher than that reported in the comparator group (3% P = 0.02). Granisetron appears to be a safe and effective agent which can be used as a single agent for the prophylaxis of cisplatin-induced emesis. The simplicity of administration, a single 5-min infusion prior to chemotherapy, and the lack of somnolence or extrapyramidal reactions offer clear advantages over the comparator combination regimen.
et al., 1985) , a previous history of nausea and vomiting from any cause (Leventhal et al., 1988; Andrykowski et al., 1985) , alcohol intake (D'Acquisto et al., 1986) and age (Morrow, 1982) -will all determine the susceptibility to cytostaticinduced nausea and vomiting.
The use of anti-emetic agents to control cytostatic-induced nausea and vomiting began with the use of single anti-emetic agents such as the dopamine antagonists, which include the phenothiazines (e.g. prochlorperazine) or the benzamide derivatives (e.g. metoclopramide). When used alone, these agents fail to adequately control emesis in up to 60% of patients (Moertel & Reitemeier, 1969; Bardfield, 1966) . This led to the development of combination anti-emetic regimens, where the classical dopamine antagonists were combined with other agents with little inherent anti-emetic activity, such as benzodiazepines or corticosteroids or both. Anti-emetic control was improved, but not substantially. Gralla et al. (1981) were the first to use high doses of metoclopramide for the prevention of emesis and demonstrated improved anti-emetic efficacy of this agent used in this way, especially in patients receiving high-dose cisplatin containing regimens where up to 40% of patients could be controlled with metoclopramide alone. Combination with corticosteroids (Grunberg et al., 1986 ) further improved control and the addition of a benzodiazepine such as lorazepam was shown to improve the subjective effectiveness of the combinations (Kris et al., 1985a ) and up to 60% of patients could now be completely controlled (Kris et al., 1987) . However, the use of these regimens is associated with a number of side effects such as extrapyramidal reactions (Kris et al., 1983) and sedation. In addition, they were cumbersome and often inconvenient to administer.
The recognition by Miner and Sanger (1986) that highdose metoclopramide exerted its anti-emetic effect via antagonism of the 5-HT subtype 3 receptor led to the development of the highly selective 5-HT3 receptor antagonist, granisetron. Early clinical studies have demonstrated the significant anti-emetic efficacy of granisetron when used as a single prophylactic agent, given as a single dose, to control emesis associated with the use of both moderately emetogenic chemotherapeutic agents (Smith, 1990 ) and highdose cisplatin (Soukop, 1990) . Complete control of emesis was achieved in up to 81% and 60% of patients respectively. The use of granisetron was not associated with extrapyramidal reactions or somnolence and the drug was generally well tolerated with the most frequent side effect being mild headache.
A comparative study has demonstrated the clear superiority of granisetron over a combination regimen of chlorpromazine and dexamethasone in the prophylaxis of moderately emetogenic cytostatic-induced emesis, where the complete response rate for each treatment group was 70% and 49% respectively (Marty, 1990) .
This study was undertaken to compare the efficacy and safety of granisetron with those of a combination anti-emetic regimen containing high-dose metoclopramide plus dexamethasone used according to a recommended schedule (ABPI Data Sheet Compendium 1989 .
Patients and methods
Patients
The study was conducted at 28 centres in four countries (France, Switzerland, UK and West Germany). Patients eligible for selection into this study were inpatients due to receive cisplatin-containing chemotherapy for the first time for the treatment of malignant disease. The chemotherapy was to be administered on a single day and cisplatin was to be administered at a minimum dose of > 49 mg m2.
Patients were excluded from the study if they had marked hepatic or renal dysfunction, active gastric ulceration, gastric compression or were suffering from acute or chronic nausea or vomiting.
All patients gave their informed consent to participate in the study and were free to withdraw at any time. The study was carried out in accordance with the declaration of Helsinki 1964 and its amendments of Tokyo (1975) Clinical and laboratory monitoring Blood pressure, pulse rate and temperature were recorded at screening examination (1-14 days prior to the day of study), immediately prior to administration of the anti-emetic and then at 6, 12, 18 and 24 h after the start of the cisplatin infusion. An ECG recording was made at screening. The clinician assessed the patient's state of alertness and general well being at these times and also at the start of cisplatin therapy and 3 h later. Blood and urine samples were taken for laboratory analysis at screening, before drug administration on the study day and 24 h later. A follow-up assessment was made after 7 days. Data obtained were compared with predetermined normal ranges for each parameter and also with the predose value.
Adverse events Adverse event occurrence was determined by asking the patient whether they felt different in any way before the adminsitration of anti-emetic and then at 6 and 24 h after the start of the cisplatin infusion, and again at the follow-up visit 7 days later. Adverse events were also recorded spontaneously by the physician who was asked to record the severity, outcome and treatment given. The physician was also required to give an assessment of the causality of the adverse event in relation to the study treatment. Adverse events were analysed for frequency and serious adverse events (defined as any event which is fatal, life threatening, disabling or incapacitating; or results in hospitalisation, prolongs hospital stay or is associated with congenital abnormality, carcinoma or overdose) were identified.
Presentation of results
Patient's response to anti-emetic therapy was classified according to the following schedule:
Complete responder Patients who experienced no emetic episodes and had no or only mild nausea in the 24 h after the administration of chemotherapy.
Major responder Patients who experienced one emetic episode or, if no emesis occurred, recorded moderate to severe nausea in the first 24 h.
Minor responder Patients who experienced two to four emetic episodes in the first 24 h irrespective of the incidence of nausea.
Failure Patients who experienced more than four emetic episodes in the first 24h irrespective of nausea.
The complete and major responder categories were combined to define the major efficacy.
Statistical analysis was performed with either the chisquared or Cox log rank test, with a 2-sided significance level of 5% regarded as being significant.
Results
Two hundred and eighty-one patients participated in the study (183 males and 98 females). A summary of demographic details are presented in Table I . One hundred and forty-three patients received anti-emetic treatment with granisetron and 138 with the comparator regimen of metoclopramide combined with dexamethasone. The groups were well matched in terms of sex and other demographic parameters. The mean dose of cisplatin was 86 mg m2 (range 20-195 mg m2) in the granisetron-treated group and 85 mg m-2 (range 20-201 mg m-2) in the comparator group.
Efficacy over 24 h
The 24-h efficacy response for patients in each treatment group is presented in Figure 1 . One hundred patients (70%) in the granisetron group and 93 patients (67%) in the com- significant. In 72% of patients receiving granisetron and 80% of patients receiving metoclopramide/dexamethasone combination, no additional anti-emetic therapy was required for the total duration of the study.
Clinical and laboratory monitoring Mean changes in pulse rate, blood pressure and temperature were small and were not significantly different between groups. At no time did the investigators rate fewer than 79% of patients in the granisetron group and 73% of patients in the comparator group as well. Alertness varied with the patients' sleep patterns and there was no discernable difference between the two groups. Analysis of laboratory investigations again revealed no clinically significant changes in parameters in either group of patients.
Adverse events During the 7-day period of study one or more adverse events were reported in 33 patients (23%) in the granisetron group and 45 patients (33%) in the metoclopramide/dexamethasone group. This was not statistically different (P = 0.07) (Table  II) . Headache was reported significantly more frequently in the granisetron group with 14 patients (9.8%) experiencing this compared to four patients (2.9%) in the comparator group (P = 0.02). This was the commonest adverse event in this treatment group. Headaches were usually mild and resolved either spontaneously or in response to treatment with a mild analgesic such as paracetamol. Other adverse events occurring in three or more patients in this group were diarrhoea and constipation. Significantly more patients in the comparator group reported diarrhoea, 7.2% compared to 2.1 % in the granisetron group (P = 0.04) and somnolence 5.1% compared to 0.7% (P = 0.03) than in the granisetron group. In addition there were significantly more extrapyramidal reactions (including extrapyramidal syndrome, dyskinesia, trismus and CNS stimulation) in the comparator group (n = 13) than in the granisetron group where none were reported (P <0.05).
Two patients in the granisetron group experienced serious adverse events during the 7-day course of the study. One patient experienced dyspnoea which resulted in the patient's death but was considered to be unrelated to granisetron therapy. Another reported severe buccal cavity haemorrhage secondary to malignant involvement which was again considered to be unrelated to therapy with granisetron. Four patients in the comparator group experienced serious adverse events. One patient had dyspnoea, tachycardia and pericarditis, a second a transient ischaemic attack, and the third acute respiratory distress and renal insufficiency. None of these events were thought to be related to anti-emetic therapy. A fourth patient experienced a severe extrapyramidal reaction which was considered to be related to treatment with metoclopramide.
Discussion
The pattern of emesis following chemotherapy is variable and is dependent on several factors, including the chemotherapeutic agent, the patient's previous history of nausea and vomiting, the patient's previous experience of chemotherapy and other patient characteristics (Roila et al., 1985; Levanthal et al., 1988; Andrykowski et al., 1985; D' Aequisto et al., 1986; Morrow, 1982) . Nausea and vomiting occurring the first 24 h following chemotherapy (acute emesis) is of particular importance in determining the pattern of emesis.
Patients experiencing poor control of acute emesis are more likely to experience delayed emesis (nausea and vomiting after the first 24 h) than patients who are protected during this period (Kris et al., 1985b; Roila et al., 1991) . Initial control of acute emesis is therefore of importance with drugs known to cause delayed emesis, such as cisplatin. In addition, patients who suffer severe acute or delayed emesis are more likely to suffer anticipatory nausea and vomiting prior to receiving repeat cycles of chemotherapy (Morrow, 1982) which may lead to the patient delaying or refusing further courses of potentially curative treatment (Wilcox et al., 1982) . Gaining control of emesis in the first 24-h period following chemotherapy can, therefore, improve the likelihood of successful management of subsequent cycles.
In this single-blind study the objective was to determine the comparative efficacy and safety of granisetron compared with the combination of high-dose metoclopramide and dexamethasone, which is commonly used to treat cisplatininduced nausea and vomiting. The anti-emetic efficacy of each treatment in the first 24 h following cytostatic therapy was not shown to be significantly different. Seventy percent of patients receiving granisetron and 67% of patients receiving the metoclopramide and dexamethasone combination were complete responders. Thirteen percent of patients in granisetron group and 9% in the comparator group were major responders with major efficacy of each treatment group being 83% and 77% respectively. There were more failures in the comparator gorup (10%) than in the granisetron group (5%) although there was little difference in the number of minor responders in either group. Thus both preparations produced effective control of symptoms during the first 24-h period. Granisetron also appears to In terms of the time to first symptoms of nausea or vomiting there was also no significant difference between the two groups, and there was no difference between the two treatment groups when assessed for global efficacy by either the patient or the clinician.
A proportion of patients in both treatment groups remained free from further nausea or vomiting in the 6 days following chemotherapy, whereas 36% of granisetron-treated patients and 47% of comparator-treated patients remained complete responders for the whole study period. It is difficult to draw any firm conclusions about this observation which may indicate that both treatments offer some protection against emesis beyond the day of chemotherapy.
The results of this study show that granisetron has a good safety profile with no serious granisetron-related adverse effects. The commonest adverse event was headache which was usually mild and resolved either spontaneously or with mild analgesia. Conversely the use of dopamine antagonists is known to be associated with a number of undesirable side effects as was seen in this study where 13 extrapyramidal reactions were reported, one of which was serious. This particular problem has been reported as occurring in up to 30% of patients taking dopamine antagonists (Kris et al., 1983 ). The effect is seen most frequently in younger patients and with increasing doses, precluding the use of these drugs at high doses for long periods of time (Kris et al., 1983) . This effect can be very distressing to the patient and may itself require treatment, adding further complication to an already cumbersome administration schedule. Granisetron does not cause extrapyramidal symptoms. This is related to the fact that it is a highly selective 5-HT3 receptor antagonist and that it has no interaction with the dopamine receptor. Indeed, it has little or no interaction with many other receptor sites (Bermudez et al., 1988) .
In addition, somnolence which was seen in 5.1% of comparator-treated patients was only observed in one patient (0.7%) treated with granisetron. Drowsiness is an undesirable side effect as patients may be unable to drive home after therapy and have to be escorted or remain in the clinic. Diarrhoea also occurred significantly more frequently in the comparator group compared with the granisetron group.
In conclusion, granisetron, when given as a convenient single 5-min infusion (40 ,ug kg-', i.v.) provided antiemetic protection comparable to that given by standard anti-emetic regimens, with the significant advantage of simplicity of administration. Granisetron is also safe to administer and is not associated with extrapyramidal effects which were associated with the comparator regimen. In addition, patients experienced significantly less side effects such as diarrhoea and somnolence with granisetron compared with the comparator.
